Table 2.

Presenting Characteristics of Rhegmatogenous Retinal Detachment in the 2020 Coronavirus Disease 2019, 2019 Primary Control, and 2018 Secondary Control Groups

	2018 Control	2019 Control	2020 Cohort
No. of patients	103	111	82
Macula-on disease (%)	44.7	49.5	24.4
VA (logMAR), median (interquartile range)	0.54 (0.18–2.00)	0.48 (0.10–2.00)	1.00(0.3–3.00)
Duration of symptoms (days), median (interquartile range)	3 (1–7)	4 (1–7)	5.5 (2–7)
Seeking treatment within 1 day of symptom onset (%)	43.7	38.7	20.0
Primary PVR (%)	3.8	4.5	13.4

logMAR = logarithm of the minimum angle of resolution; PVR = proliferative vitreoretinopathy; VA = visual acuity.

No difference was found in the presenting characteristics between the 2018 and 2019 control groups. A significant decrease was found in patients with macula-on disease at presentation (P < 0.001), a significant decrease was found in the proportion of patients seeking treatment within 1 day of symptoms (P = 0.005), and significant increase was found in the proportion of patients with primary PVR at presentation (P = 0.03) in the 2020 cohort compared with the 2019 control group. The median logMAR VA was worse for the 2020 cohort compared with the 2019 control group, with a significant difference in distributions (P = 0.008). P < 0.05 significance shown in boldface.